Loss of chromosome Y in regulatory T cells.
GSEA
Gene set enrichment analysis
LOY
Mosaic loss of chromosome Y
Regulatory T cells
Single-cell RNA sequencing
Tregs
scRNA-seq
scRNAseq
Journal
BMC genomics
ISSN: 1471-2164
Titre abrégé: BMC Genomics
Pays: England
ID NLM: 100965258
Informations de publication
Date de publication:
05 Mar 2024
05 Mar 2024
Historique:
received:
27
07
2023
accepted:
28
02
2024
medline:
6
3
2024
pubmed:
6
3
2024
entrez:
5
3
2024
Statut:
epublish
Résumé
Mosaic loss of chromosome Y (LOY) in leukocytes is the most prevalent somatic aneuploidy in aging humans. Men with LOY have increased risks of all-cause mortality and the major causes of death, including many forms of cancer. It has been suggested that the association between LOY and disease risk depends on what type of leukocyte is affected with Y loss, with prostate cancer patients showing higher levels of LOY in CD4 + T lymphocytes. In previous studies, Y loss has however been observed at relatively low levels in this cell type. This motivated us to investigate whether specific subsets of CD4 + T lymphocytes are particularly affected by LOY. Publicly available, T lymphocyte enriched, single-cell RNA sequencing datasets from patients with liver, lung or colorectal cancer were used to study how LOY affects different subtypes of T lymphocyte. To validate the observations from the public data, we also generated a single-cell RNA sequencing dataset comprised of 23 PBMC samples and 32 CD4 + T lymphocytes enriched samples. Regulatory T cells had significantly more LOY than any other studied T lymphocytes subtype. Furthermore, LOY in regulatory T cells increased the ratio of regulatory T cells compared with other T lymphocyte subtypes, indicating an effect of Y loss on lymphocyte differentiation. This was supported by developmental trajectory analysis of CD4 + T lymphocytes culminating in the regulatory T cells cluster most heavily affected by LOY. Finally, we identify dysregulation of 465 genes in regulatory T cells with Y loss, many involved in the immunosuppressive functions and development of regulatory T cells. Here, we show that regulatory T cells are particularly affected by Y loss, resulting in an increased fraction of regulatory T cells and dysregulated immune functions. Considering that regulatory T cells plays a critical role in the process of immunosuppression; this enrichment for regulatory T cells with LOY might contribute to the increased risk for cancer observed among men with Y loss in leukocytes.
Sections du résumé
BACKGROUND
BACKGROUND
Mosaic loss of chromosome Y (LOY) in leukocytes is the most prevalent somatic aneuploidy in aging humans. Men with LOY have increased risks of all-cause mortality and the major causes of death, including many forms of cancer. It has been suggested that the association between LOY and disease risk depends on what type of leukocyte is affected with Y loss, with prostate cancer patients showing higher levels of LOY in CD4 + T lymphocytes. In previous studies, Y loss has however been observed at relatively low levels in this cell type. This motivated us to investigate whether specific subsets of CD4 + T lymphocytes are particularly affected by LOY. Publicly available, T lymphocyte enriched, single-cell RNA sequencing datasets from patients with liver, lung or colorectal cancer were used to study how LOY affects different subtypes of T lymphocyte. To validate the observations from the public data, we also generated a single-cell RNA sequencing dataset comprised of 23 PBMC samples and 32 CD4 + T lymphocytes enriched samples.
RESULTS
RESULTS
Regulatory T cells had significantly more LOY than any other studied T lymphocytes subtype. Furthermore, LOY in regulatory T cells increased the ratio of regulatory T cells compared with other T lymphocyte subtypes, indicating an effect of Y loss on lymphocyte differentiation. This was supported by developmental trajectory analysis of CD4 + T lymphocytes culminating in the regulatory T cells cluster most heavily affected by LOY. Finally, we identify dysregulation of 465 genes in regulatory T cells with Y loss, many involved in the immunosuppressive functions and development of regulatory T cells.
CONCLUSIONS
CONCLUSIONS
Here, we show that regulatory T cells are particularly affected by Y loss, resulting in an increased fraction of regulatory T cells and dysregulated immune functions. Considering that regulatory T cells plays a critical role in the process of immunosuppression; this enrichment for regulatory T cells with LOY might contribute to the increased risk for cancer observed among men with Y loss in leukocytes.
Identifiants
pubmed: 38443832
doi: 10.1186/s12864-024-10168-7
pii: 10.1186/s12864-024-10168-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
243Informations de copyright
© 2024. The Author(s).
Références
Forsberg LA, Gisselsson D, Dumanski JP. Mosaicism in health and disease — clones picking up speed. Nat Rev Genet. 2017;18:128–42. https://doi.org/10.1038/nrg.2016.145 .
doi: 10.1038/nrg.2016.145
pubmed: 27941868
Zhou W, et al. Mosaic loss of chromosome Y is associated with common variation near TCL1A. Nat Genet. 2016;48:563–8. https://doi.org/10.1038/ng.3545 .
doi: 10.1038/ng.3545
pubmed: 27064253
pmcid: 4848121
Thompson DJ, et al. Genetic predisposition to mosaic Y chromosome loss in blood. Nature. 2019;575:652–7. https://doi.org/10.1038/s41586-019-1765-3 .
doi: 10.1038/s41586-019-1765-3
pubmed: 31748747
pmcid: 6887549
Forsberg LA, et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet. 2014;46:624–8. https://doi.org/10.1038/ng.2966 .
doi: 10.1038/ng.2966
pubmed: 24777449
pmcid: 5536222
Loftfield E, et al. Predictors of mosaic chromosome Y loss and associations with mortality in the UK Biobank. Sci Rep. 2018;8:12316. https://doi.org/10.1038/s41598-018-30759-1 .
doi: 10.1038/s41598-018-30759-1
pubmed: 30120341
pmcid: 6098142
Haitjema S, et al. Loss of Y chromosome in blood is Associated with Major Cardiovascular events during Follow-Up in men after Carotid Endarterectomy. Circ Cardiovasc Genet. 2017;10:e001544. https://doi.org/10.1161/CIRCGENETICS.116.001544 .
doi: 10.1161/CIRCGENETICS.116.001544
pubmed: 28768751
Sano S, et al. Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality. Science. 2022;377:292–7. https://doi.org/10.1126/science.abn3100 .
doi: 10.1126/science.abn3100
pubmed: 35857592
pmcid: 9437978
Ganster C, et al. New data shed light on Y-loss-related pathogenesis in myelodysplastic syndromes. Genes Chromosomes Cancer. 2015;54:717–24. https://doi.org/10.1002/gcc.22282 .
doi: 10.1002/gcc.22282
pubmed: 26394808
Dumanski JP, et al. Mosaic loss of chromosome Y in blood is Associated with Alzheimer Disease. Am J Hum Genet. 2016;98:1208–19. https://doi.org/10.1016/j.ajhg.2016.05.014 .
doi: 10.1016/j.ajhg.2016.05.014
pubmed: 27231129
pmcid: 4908225
Terao C, et al. GWAS of mosaic loss of chromosome Y highlights genetic effects on blood cell differentiation. Nat Commun. 2019;10:4719. https://doi.org/10.1038/s41467-019-12705-5 .
doi: 10.1038/s41467-019-12705-5
pubmed: 31624269
pmcid: 6797717
Lin SH, et al. Mosaic chromosome Y loss is associated with alterations in blood cell counts in UK Biobank men. Sci Rep. 2020;10:3655. https://doi.org/10.1038/s41598-020-59963-8 .
doi: 10.1038/s41598-020-59963-8
pubmed: 32108144
pmcid: 7046668
Dumanski JP, et al. Immune cells lacking Y chromosome show dysregulation of autosomal gene expression. Cell Mol Life Sci. 2021;78:4019–33. https://doi.org/10.1007/s00018-021-03822-w .
doi: 10.1007/s00018-021-03822-w
pubmed: 33837451
pmcid: 8106578
Mattisson J, et al. Leukocytes with chromosome Y loss have reduced abundance of the cell surface immunoprotein CD99. Sci Rep. 2021;11:15160. https://doi.org/10.1038/s41598-021-94588-5 .
doi: 10.1038/s41598-021-94588-5
pubmed: 34312421
pmcid: 8313698
Bruhn-Olszewska B, et al. Loss of Y in leukocytes as a risk factor for critical COVID-19 in men. Genome Med. 2022;14:139. https://doi.org/10.1186/s13073-022-01144-5 .
doi: 10.1186/s13073-022-01144-5
pubmed: 36514076
pmcid: 9747543
Baron U, et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3 + conventional T cells. Eur J Immunol. 2007;37:2378–89. https://doi.org/10.1002/eji.200737594 .
doi: 10.1002/eji.200737594
pubmed: 17694575
Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of Cd4 + Cd25 + T cells with Regulatory properties from Human Blood. J Exp Med. 2001;193:1303–10. https://doi.org/10.1084/jem.193.11.1303 .
doi: 10.1084/jem.193.11.1303
pubmed: 11390437
pmcid: 2193384
Sakaguchi S, et al. Regulatory T cells and human disease. Annu Rev Immunol. 2020;38:541–66. https://doi.org/10.1146/annurev-immunol-042718-041717 .
doi: 10.1146/annurev-immunol-042718-041717
pubmed: 32017635
Rocamora-Reverte L, Melzer FL, Würzner R, Weinberger B. The Complex Role of Regulatory T Cells in immunity and aging. Front Immunol. 2020;11:616949. https://doi.org/10.3389/fimmu.2020.616949 .
doi: 10.3389/fimmu.2020.616949
pubmed: 33584708
Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27:109–18. https://doi.org/10.1038/cr.2016.151 .
doi: 10.1038/cr.2016.151
pubmed: 27995907
Ménétrier-Caux C, et al. Targeting regulatory T cells. Target Oncol. 2012;7:15–28. https://doi.org/10.1007/s11523-012-0208-y .
doi: 10.1007/s11523-012-0208-y
pubmed: 22327882
Abdel-Hafiz HA, et al. Y chromosome loss in cancer drives growth by evasion of adaptive immunity. Nature. 2023;619:624–31. https://doi.org/10.1038/s41586-023-06234-x .
doi: 10.1038/s41586-023-06234-x
pubmed: 37344596
Zheng C, et al. Landscape of infiltrating T cells in Liver Cancer revealed by single-cell sequencing. Cell. 2017;169:1342–1356e1316. https://doi.org/10.1016/j.cell.2017.05.035 .
doi: 10.1016/j.cell.2017.05.035
pubmed: 28622514
Guo X, et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med. 2018;24:978–85. https://doi.org/10.1038/s41591-018-0045-3 .
doi: 10.1038/s41591-018-0045-3
pubmed: 29942094
Zhang L, et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature. 2018;564:268–72. https://doi.org/10.1038/s41586-018-0694-x .
doi: 10.1038/s41586-018-0694-x
pubmed: 30479382
Vermeulen MC, Pearse R, Young-Pearse T, Mostafavi S. Mosaic loss of chromosome Y in aged human microglia. Genome Res. 2022;32:1795–807. https://doi.org/10.1101/gr.276409.121 .
doi: 10.1101/gr.276409.121
pubmed: 36041859
pmcid: 9712627
Barnes MJ, et al. CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria. Mucosal Immunol. 2013;6:324–34. https://doi.org/10.1038/mi.2012.75 .
doi: 10.1038/mi.2012.75
pubmed: 22910217
Zhao H, Liao X, Kang Y, Tregs. Where we are and what comes next? Front Immunol. 2017;8:1578. https://doi.org/10.3389/fimmu.2017.01578 .
doi: 10.3389/fimmu.2017.01578
pubmed: 29225597
pmcid: 5705554
Peeters SB, et al. How do genes that escape from X-chromosome inactivation contribute to Turner syndrome? Am J Med Genet C Semin Med Genet. 2019;181:28–35. https://doi.org/10.1002/ajmg.c.31672 .
doi: 10.1002/ajmg.c.31672
pubmed: 30779428
Goudarzi KM, Lindström MS. Role of ribosomal protein mutations in tumor development (review). Int J Oncol. 2016;48:1313–24. https://doi.org/10.3892/ijo.2016.3387 .
doi: 10.3892/ijo.2016.3387
pubmed: 26892688
pmcid: 4777597
Genuth NR, Barna M. The Discovery of Ribosome Heterogeneity and its implications for Gene Regulation and Organismal Life. Mol Cell. 2018;71:364–74. https://doi.org/10.1016/j.molcel.2018.07.018 .
doi: 10.1016/j.molcel.2018.07.018
pubmed: 30075139
pmcid: 6092941
Goodfellow P, Pym B, Mohandas T, Shapiro LJ. The cell surface antigen locus, MIC2X, escapes X-inactivation. Am J Hum Genet. 1984;36:777–82.
pubmed: 6540985
pmcid: 1684497
Zhang L, Zhu T, Miao H, Liang B. The calcium binding protein S100A11 and its roles in diseases. Front Cell Dev Biol. 2021;9:693262. https://doi.org/10.3389/fcell.2021.693262 .
doi: 10.3389/fcell.2021.693262
pubmed: 34179021
pmcid: 8226020
Poeter M, et al. Disruption of the annexin A1/S100A11 complex increases the migration and clonogenic growth by dysregulating epithelial growth factor (EGF) signaling. Biochim Biophys Acta. 2013;1833:1700–11. https://doi.org/10.1016/j.bbamcr.2012.12.006 .
doi: 10.1016/j.bbamcr.2012.12.006
pubmed: 23246849
de Graauw M, et al. Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci U S A. 2010;107:6340–5. https://doi.org/10.1073/pnas.0913360107 .
doi: 10.1073/pnas.0913360107
pubmed: 20308542
pmcid: 2852023
He H, Li J, Weng S, Li M, Yu Y. S100A11: diverse function and Pathology corresponding to different target proteins. Cell Biochem Biophys. 2009;55:117. https://doi.org/10.1007/s12013-009-9061-8 .
doi: 10.1007/s12013-009-9061-8
pubmed: 19649745
Yang YH, et al. Deficiency of annexin A1 in CD4 + T cells exacerbates T cell-dependent inflammation. J Immunol. 2013;190:997–1007. https://doi.org/10.4049/jimmunol.1202236 .
doi: 10.4049/jimmunol.1202236
pubmed: 23267026
de Jong R, Leoni G, Drechsler M, Soehnlein O. The advantageous role of annexin A1 in cardiovascular disease. Cell Adh Migr. 2017;11:261–74. https://doi.org/10.1080/19336918.2016.1259059 .
doi: 10.1080/19336918.2016.1259059
pubmed: 27860536
Grewal T, Wason SJ, Enrich C, Rentero C. Annexins– insights from knockout mice. Biol Chem. 2016;397:1031–53. https://doi.org/10.1515/hsz-2016-0168 .
doi: 10.1515/hsz-2016-0168
pubmed: 27318360
Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. TIGIT, the next step towards successful combination Immune Checkpoint Therapy in Cancer. Front Immunol. 2021;12:699895. https://doi.org/10.3389/fimmu.2021.699895 .
doi: 10.3389/fimmu.2021.699895
pubmed: 34367161
pmcid: 8339559
Huang Z, Qi G, Miller JS, Zheng SG. CD226: an emerging role in Immunologic diseases. Front Cell Dev Biol. 2020;8:564. https://doi.org/10.3389/fcell.2020.00564 .
doi: 10.3389/fcell.2020.00564
pubmed: 32850777
pmcid: 7396508
Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10:48–57. https://doi.org/10.1038/ni.1674 .
doi: 10.1038/ni.1674
pubmed: 19011627
Joller N, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011;186:1338–42. https://doi.org/10.4049/jimmunol.1003081 .
doi: 10.4049/jimmunol.1003081
pubmed: 21199897
Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT/CD226 axis regulates human T cell function. J Immunol. 2012;188:3869–75. https://doi.org/10.4049/jimmunol.1103627 .
doi: 10.4049/jimmunol.1103627
pubmed: 22427644
Kurtulus S, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125:4053–62. https://doi.org/10.1172/jci81187 .
doi: 10.1172/jci81187
pubmed: 26413872
pmcid: 4639980
Fourcade J, et al. CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight. 2018;3. https://doi.org/10.1172/jci.insight.121157 .
Lu L, Barbi J, Pan F. The regulation of immune tolerance by FOXP3. Nat Rev Immunol. 2017;17:703–17. https://doi.org/10.1038/nri.2017.75 .
doi: 10.1038/nri.2017.75
pubmed: 28757603
pmcid: 5793224
Bennett CL, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20–1. https://doi.org/10.1038/83713 .
doi: 10.1038/83713
pubmed: 11137993
Zheng Y, et al. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 2007;445:936–40. https://doi.org/10.1038/nature05563 .
doi: 10.1038/nature05563
pubmed: 17237761
Chen C, Rowell EA, Thomas RM, Hancock WW, Wells AD. Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J Biol Chem. 2006;281:36828–34. https://doi.org/10.1074/jbc.M608848200 .
doi: 10.1074/jbc.M608848200
pubmed: 17028180
Zheng GXY, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017;8:14049. https://doi.org/10.1038/ncomms14049 .
doi: 10.1038/ncomms14049
pubmed: 28091601
pmcid: 5241818